Patients treated with fg-SRLs plus Peg-V and those treated with Pasi-LAR did not differ for gender, age, GH and IGF-I levels at acromegaly diagnosis, at baseline and at the last follow-up, concomitant hypopituitarism, GHR polymorphisms, frequency of p-VFs, and acromegaly outcome, as detailed in Table 1. This evidence concerns the gene GHR and acromegaly.